Evidence map›Paper›PMID 27536366›Full record

ArticleUnited European gastroenterology journal2016

Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis.

Andrea Tenca, Martti Färkkilä, Johanna Arola, Tytti Jaakkola, Roberto Penagini, Kaija-Leena Kolho

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in United European gastroenterology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cholangitis: Diagnosis, Treatment and Prognosis.Journal of clinical and translational hepatology · 2017
    Review
  7. Autoimmune hepatitis: current challenges and future prospects.Clinical and experimental gastroenterology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Andrea TencaClinic of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Martti FärkkiläClinic of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Johanna ArolaDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tytti JaakkolaDepartment of Pediatric Gastroenterology, University of Helsinki and Children's Hospital, Helsinki, Finland.
Roberto PenaginiGastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Kaija-Leena KolhoDepartment of Pediatric Gastroenterology, University of Helsinki and Children's Hospital, Helsinki, Finland.
University of Helsinki · FIFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe natural history of pediatric-onset primary sclerosing cholangitis (PSC) and overlap with autoimmune hepatitis (PSC/AIH) is poorly known.

objectiveThe aim of this study was to evaluate the clinical outcome of patients with pediatric-onset disease in a tertiary referral center.

methodsWe traced 33 patients (median age at diagnosis 16 years), with PSC or PSC/AIH in cholangiography and liver histology diagnosed between December 1993 and 2011, at Helsinki University Hospital. Diagnostic procedures and long-term follow-up were reassessed until the end of December 2013.

resultsPSC was confirmed in all 33 patients; 19 of them had an overlap with AIH. At diagnosis, three of 33 had cirrhosis. Inflammatory bowel disease (IBD) was associated in 76% of the patients, mostly ulcerative colitis (70%); treatment of IBD being a minor determinant of the clinical outcome of liver disease. In the last follow-up (median nine years), all patients were alive, and no malignancy occurred. Most patients (91%) were on ursodeoxycholic acid and 12 PSC/AIH patients on immunosuppression. Endoscopic retrograde cholangiography during follow-up showed a progression of intra-hepatic disease in 12 patients (36%). Four patients (12%) had undergone liver transplantation, and one was listed; no recurrence of the disease in the graft was seen.

conclusionThe clinical course and outcome of pediatric-onset PSC and PSC/AIH seem to be favourable in the majority of patients until early adulthood. In about one-third of patients, however, PSC is progressive, challenging the current treatment guidelines and warranting further studies on disease pathogenesis.

Indexed as

cirrhosisinflammatory bowel diseaseliver transplantationPediatricprimary sclerosing cholangitis

Identifiers

PMID27536366
PMCPMC4971785
OpenAlexW2236070851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.